Prima BioMed to Maintain NASDAQ Listing
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwired) -- 06/04/15 -- Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"), announces that, further to the announcement made on 29 December 2014, it has received a notice, dated 3 June 2015 from the Listing Qualifications Department of The NASDAQ Stock Market, indicating that, for the 10 consecutive business days from 19 May 2015 to 2 June 2015, the closing bid price of the Company's American Depositary Shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1) ("the Minimum Bid Price Rule") and the Company's shares will remain listed on The NASDAQ Global Market.
Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
Prima's original product, called CVac, is an ex vivo dendritic cell priming therapy that in May 2015 yielded favourable Phase II data in second remission ovarian cancer patients. Prima is currently seeking partners for further development of this therapy. Prima's current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is soluble LAG-3, is a T cell immunostimulatory factor for cancer chemoimmunotherapy which has completed early Phase II trials. A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
Prima BioMed is listed on the Australian stock exchange and on the NASDAQ in the US. For further information please visit
Stuart Roberts
Global Head of Investor Relations
+61 (0) 447 247 909
Adam Holdsworth
ProActive Capital
+1 (646) 862 4607
Mr Matthew Gregorowski
Citadel Communications
+61 (0) 422 534 755
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.06.2015 - 11:00 Uhr
Sprache: Deutsch
News-ID 398174
Anzahl Zeichen: 0
contact information:
Town:
SYDNEY, AUSTRALIA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 193 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prima BioMed to Maintain NASDAQ Listing"
steht unter der journalistisch-redaktionellen Verantwortung von
Prima BioMed Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
